Sort
48,018 grants matching “immunotherapy”
Mechanisms Underlying the Role of Interleukin-7 in Type 1 Diabetes
$424,766Hans Peter Dooms · Boston University Medical Campus · R01 · FY2020 · DK
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer
$424,710Lauren Averett Byers · Ut Southwestern Medical Center · P50 · FY2023 · CA
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer
$424,709Lauren Averett Byers · Ut Southwestern Medical Center · P50 · FY2022 · CA
Administrative Supplement: Stratifying Patient Immune Endotypes in Sepsis (SPIES Study)
$424,705Lyle L Moldawer · University Of Florida · R01 · FY2022 · GM
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach
$424,639Maurizio Pellecchia · University Of California Riverside · R01 · FY2023 · CA
Mcl-1/Bfl-1 in apoptosis and signal transduction: a structure/function approach
$424,639Maurizio Pellecchia · University Of California Riverside · R01 · FY2022 · CA
CAREER DEVELOPMENT IN PEDIATRIC AND MEDICAL ONCOLOGY
$424,632Fred Hutchinson Cancer Research Center · K12 · FY2001 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$424,612Lei Zheng · Johns Hopkins University · R01 · FY2016 · CA
Reprogramming the pancreatic tumor microenvironment with immunotherapy
$424,612Lei Zheng · Johns Hopkins University · R01 · FY2015 · CA
Project 1
$424,583Mark A Atkinson · University Of Florida · P01 · FY2023 · AI
Promoting Lead Academic Participating Sites (LAPS) Studies Accrual and Lung cancer Screening in Oklahoma
$424,480Raid Aljumaily · University Of Oklahoma Hlth Sciences Ctr · R50 · FY2025 · CA
EXPRESSION OF TUBERCULOSIS IN THE LUNG
$424,448Univ Of Med/Dent Of Nj-Nj Medical School · R01 · FY2001 · HL
Immune activation by necroptotic cell death
$424,373Andrew Atwell Oberst · University Of Washington · R01 · FY2021 · CA
Collaborative Innate-Adaptive Immune Regulation of Tumor Progression
$424,356Matthew F Krummel · University Of California, San Francisco · U01 · FY2010 · CA
Neuroprotective Treatment Trial Planning in REM Sleep Behavior Disorder
$424,342Yo-El S Ju · Washington University · R34 · FY2019 · AG
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma
$424,213Gregory B. Lesinski · Emory University · R01 · FY2020 · CA
Using Nonclassical Estrogen Signaling to Prevent Melanoma
$424,200Todd W Ridky · University Of Pennsylvania · R01 · FY2022 · CA
CRISPR gene therapies targeting tau in Alzheimer's disease and tauopathies
$424,095Todd Jonathan Cohen · Univ Of North Carolina Chapel Hill · R21 · FY2023 · AG
Genetic Mechanisms Controlling Kidney Cancer Immune Escape
$424,094Haydn Kissick · Emory University · R01 · FY2024 · CA
Macrophage-based ovarian cancer immunotherapy
$424,055Fiona E Yull · Vanderbilt University · R01 · FY2021 · CA
Pathogenesis of microbial anterior eye diseases
$424,052Gerald B Pier · Brigham And Women'S Hospital · R01 · FY2014 · EY
Exploring novel therapeutic strategies for combinatory therapy to treat renal clear cell carcinomas
$424,015Weizhou Zhang · University Of Florida · R01 · FY2024 · CA
Tissue-Based Cytokine Immunotherapy for Skin Cancer
$423,965Mary A. Lokuta · Stratatech Corporation · R44 · FY2010 · CA
Anti-Sox2 immunotherapy to prevent multiple myeloma relapse
$423,948Alfred L. Garfall · University Of Pennsylvania · R21 · FY2020 · CA
Mechanisms of the Induction of Oral Tolerance
$423,878Howard L Weiner · Brigham And Women'S Hospital · R01 · FY2014 · AI